<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939989</url>
  </required_header>
  <id_info>
    <org_study_id>M15-942</org_study_id>
    <secondary_id>2016-002491-26</secondary_id>
    <nct_id>NCT02939989</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study</brief_title>
  <acronym>MAGELLAN-3</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of co-administration of
      ABT-493/ABT-530 plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV)
      genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic
      participants) who have experienced virologic failure in an AbbVie parent clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">June 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>Percentage of participants with hepatitis C virus ribonucleic acid less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment virologic failure.</measure>
    <time_frame>Treatment Day 1 to end of treatment (up to 12 or 16 weeks depending on treatment arm)</time_frame>
    <description>On treatment virologic failure is defined as confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurement of &gt; 1 log10 IU/mL above nadir) at any time point during treatment; or confirmed HCV RNA ≥ 100 IU/mL (defined as 2 consecutive HCV RNA measurements ≥ 100 IU/mL) after HCV RNA &lt; LLOQ during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment HCV virologic relapse</measure>
    <time_frame>Up to 24 weeks after last dose of study drug</time_frame>
    <description>Percentage of participants with confirmed quantifiable HCV RNA after completion of treatment among participants with unquantifiable HCV RNA at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + RBV (600 - 1200 mg) daily in two divided doses (based on baseline age and weight) for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 (300/120 mg) QD + SOF (400 mg) QD + RBV (600 - 1200 mg) daily in two divided doses (based on baseline age and weight) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
    <other_name>SOVALDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493/ABT-530</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 12 weeks</arm_group_label>
    <arm_group_label>ABT-493/ABT-530 + SOF + RBV for 16 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects must be adults (18 years of age or older) or adolescents (12
             to less than 18 years of age weighing at least 35 kg).

          -  Subject must have experienced virologic failure during or after treatment with
             ABT-493/ABT-530 in an AbbVie HCV parent study. Subjects who have experienced virologic
             failure during or after receiving ombitasvir/paritaprevir/r + dasabuvir (3D), or
             ombitasvir/paritaprevir/r (2D) in an AbbVie HCV parent study may be enrolled at
             AbbVie's discretion. Treatment in the parent study must have been completed or
             discontinued at least 1 month prior to the Screening Visit.

          -  Subjects must be able to understand and adhere to the study visit schedule and all
             other protocol requirements.

          -  Cirrhotic Subjects must have compensated cirrhosis, (Child-Pugh score of ≤ 6) at
             Screening and no current or past evidence of Child-Pugh B or C Classification or no
             clinical history of liver decompensation, including ascites noted on physical exam,
             hepatic encephalopathy or esophageal variceal bleeding.

          -  Cirrhotic Subjects must have absence of hepatocellular carcinoma (HCC) as indicated by
             a negative ultrasound (US), computed tomography (CT) scan or magnetic resonance
             imaging (MRI) within 3 months prior to Screening or a negative US at Screening.

        Exclusion Criteria:

          -  History of severe, life-threatening or other clinically significant sensitivity to any
             study drug or drug component.

          -  Female subject who is pregnant, breastfeeding or is considering becoming pregnant
             during the study or for 4 months after the last dose of study drug, or as directed per
             the local RBV label, whichever is more restrictive.

          -  Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse that could preclude adherence to the protocol in the opinion of the
             investigator, and failure in an AbbVie HCV parent study due to non-virologic reasons.

          -  Positive test result at Screening for hepatitis B surface antigen (HBsAg).

          -  Screening laboratory analyses showing calculated creatinine clearance &lt; 30 mL/min.

          -  Discontinuation from the AbbVie HCV parent study for reasons other than virologic
             failure (e.g., non-adherence, lost to follow-up, and/or the occurrence of an adverse
             event).

          -  Receipt of any HCV treatment after failing the treatment regimen in the AbbVie HCV
             parent study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Health Specialists of the Southeast /ID# 155719</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group /ID# 155714</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Associates - Baltimore /ID# 155713</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 155720</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Buffalo /ID# 155721</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Center For Liver Dis /ID# 155731</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One /ID# 155729</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TX Liver Inst, Americ Res Corp /ID# 157881</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital /ID# 200944</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 155727</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Infectologia Emilio Ribas /ID# 216489</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01246-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary /ID# 155726</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Di Tan Hospital, Capital Medical University /ID# 218496</name>
      <address>
        <city>Beijing</city>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University /ID# 217613</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mauss, Schmutz, Hegener, Athma /ID# 155592</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg /ID# 155733</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center /ID# 214844</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital /ID# 155728</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital /ID# 200945</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital /ID# 155591</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Company Hepatolog /ID# 214314</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Puerta de Hierro /ID# 155734</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Univ Sjukhuset /ID# 155735</name>
      <address>
        <city>Solna</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Universitaetsklinik /ID# 155716</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital /ID# 155718</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wyles D, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.</citation>
    <PMID>30857780</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C (HCV)</keyword>
  <keyword>HCV Genotype 1 (HCV GT1)</keyword>
  <keyword>HCV Genotype 2 (HCV GT2)</keyword>
  <keyword>HCV Genotype 3 (HCV GT3)</keyword>
  <keyword>HCV Genotype 4 (HCV GT4)</keyword>
  <keyword>HCV Genotype 5 (HCV GT5)</keyword>
  <keyword>HCV Genotype 6 (HCV GT6)</keyword>
  <keyword>Compensated Cirrhosis</keyword>
  <keyword>Non-cirrhotics</keyword>
  <keyword>Virologic failure</keyword>
  <keyword>Hepatitis C Virus Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

